Liquid biopsy test for early ovarian cancer detection
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 75 years old.
- You have been diagnosed with ovarian cancer by a doctor or biopsy.
- You have not started any treatment for ovarian cancer yet (like surgery, chemo, or other therapies).
- You are able to give permission to take part in the study.
- You do not have another active cancer, serious infection, or have had an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
This trial checks whether a “liquid biopsy,” a blood test, can help doctors tell apart different causes of a suspicious pelvic/ovarian mass and help with early detection. It may help avoid uncertainty before surgery by adding test results from blood along with imaging and standard markers.
This study is testing a new blood test (called the EARLY panel) to see how well it can detect ovarian cancer in postmenopausal women aged 50–74. It aims to find out if the test is accurate and practical for routine screening.
This study collects a blood sample before you have surgery or a biopsy for an ovarian mass. Researchers will test whether a new blood test can accurately identify ovarian cancer by looking at DNA patterns in your blood. The results will help doctors understand if this blood test could help detect ovarian cancer earlier in the future.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.